Date: 2015-05-20
Type of information: Collaboration agreement
Compound: My Adherence Program™
Company: Amag Pharmaceuticals (USA - MA) NurseWise® (USA)
Therapeutic area: Women health
Type agreement: collaboration
Action mechanism: My Adherence Program™ is a new program designed to facilitate improved patient compliance with Makena® (hydroxyprogesterone caproate injection) therapy. Makena® is the only FDA-approved treatment indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have delivered one preterm baby spontaneously in the past. Makena is a weekly injection administered by a healthcare provider, starting as early as week 16 of the pregnancy, and given weekly until week 37 or the baby is born, whichever occurs first.
Disease:
Details: * On May 20, 2015, AMAG Pharmaceuticals, a specialty pharmaceutical company, announced its Lumara Health division is partnering with NurseWise®, a national nurse triage and health education provider, to launch My Adherence Program™. This new program is designed to facilitate improved patient compliance with Makena® (hydroxyprogesterone caproate injection) therapy. Each expecting mother who has been prescribed Makena and enrolls (at no additional cost) in My Adherence Program will be paired with a dedicated maternal health nursing specialist who will contact the patient weekly to: Educate patients on the importance of achieving a full-term pregnancy; Provide educational materials that address important topics during pregnancy, such as coping with stress, good nutrition, relaxation techniques, and when applicable, recommendations for stopping smoking and drug use during pregnancy; Encourage adherence to the weekly Makena injection schedule; Identify barriers to adherence and provide potential solutions to overcome those barriers; and Empower patients to take an active role in their health. Some of the key features of My Adherence Program include Weekly telephonic patient outreach by a dedicated maternal health nursing specialist; Notification to the patient\'s healthcare provider through a HIPAA-compliant and secure platform, as needed; Data collection regarding compliance, including patient-reported reasons for missing injections or discontinuing therapy; and 24/7 availability of maternal health nursing specialists to answer certain patient questions Women who are prescribed Makena and meet the FDA-approved indication are eligible to participate in the program. Along with patients\' healthcare providers, the Makena Care Connection, a dedicated customer support program provided by Lumara Health, a division of AMAG, will introduce patients to the My Adherence Program when facilitating the prescription process and screening patients for financial assistance.
Financial terms:
Latest news:
